AUSTIN, Texas – Sheena Jonathan, Co-Founder and Director of Natera, Inc. (NASDAQ:NTRA), announced the sale of shares of the Company's common stock totaling approximately $909,125. The transactions, which were executed on January 2, 2025, were conducted under a Rule 10b5-1 trading plan. The sale comes as Natera stock trades near its 52-week high of $175.63, having generated an impressive 180% return over the past year. according to InvestingPro Through the analysis, the company maintains a good financial health rating despite the current concerns regarding market valuation.
The sales included multiple transactions at prices ranging from $158.71 to $160.70 per share. Following these transactions, Jonathan retains direct ownership of 254,372 shares and indirect ownership of 44,782 shares through the Caraluna 1 and Caraluna 2 Trusts.
These sales are part of a predetermined trading plan, allowing insiders to sell a predetermined number of shares at specific times.
In other recent news, Natera Company (Nasdaq:). has expanded its patent infringement lawsuit against NeoGenomics (NASDAQ:), Inc., with an additional patent included in the ongoing litigation. The company also reported record third-quarter revenue of $439.8 million, representing a 64% year-over-year increase, and performed 137,000 oncology tests, an increase of 54% from the previous year. Analysts TD Cowen, Baird and Jefferies maintained positive ratings on Natera stock and raised their price targets, reflecting confidence in the company's future performance.
In other developments, Natera has amended the agreement with Dr. Rabinovich, CEO, to continue in his role on the terms set forth in the agreement. However, the company faced a setback in a false advertising lawsuit against it Guardian health (NASDAQ:), but plans to ask the court to overturn the ruling. These latest developments provide investors with insight into Natera's current position.
This article was created with the power of artificial intelligence and reviewed by an editor. For more information, see our terms and conditions.
